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Prostanoids are products of cyclooxygenase biosynthetic pathways and constitute a 
family of lipidic mediators of widely diverse structures and biological actions. Besides 
their known proinflammatory role, numerous works have revealed the anti-inflammatory 
effects of various prostanoids and established their role in the resolution of 
inflammation. Among these, prostaglandins with cyclopentenone structure (cyPG) are 
electrophilic lipids that may act through various mechanisms, including the activation of 
nuclear and membrane receptors and, importantly, direct addition to protein cysteine 
residues and modification of protein function. Due to their ability to influence cysteine 
modification–mediated signaling, cyPG may play a critical role in the interplay between 
redox and inflammatory signaling pathways. Moreover, cellular redox status modulates 
cyPG addition to proteins; thus, a reciprocal regulation exists between these two factors. 
After initial controversy, it is becoming clear that endogenous cyPG are generated at 
concentrations sufficient to promote inflammatory resolution. As for other prostanoids, 
cyPG effects are highly dependent on context factors and they may exert pro- or anti-
inflammatory actions in a cell type–dependent manner, or even biphasic or dual actions 
in a given cell type or tissue. In light of the growing number of cyPG protein targets 
identified, cyPG resemble other pleiotropic mediators acting through protein 
modification. However, their complex structure results in an inter- and intramolecular 
selectivity of the residues being modified, thus opening the way for structure-activity and 
drug discovery studies. Detailed characterization of cyPG interactions with cellular 
proteins will help us to understand their mechanism of action fully and establish their 
therapeutic potential in inflammation. 
KEYWORDS: cyclopentenone prostaglandins, 15d-PGJ2, PPAR, proteomic studies, cysteine 
modification, electrophilic lipids, redox regulation 
 
GENERAL ASPECTS OF ANTI-INFLAMMATORY PROSTANOIDS 
The term prostanoids refers to lipids derived from 20 carbon fatty acids by the action of the enzymes 
called cyclooxygenases (COX), namely prostaglandins (PG) and thromboxane (TX). Prostanoids are 
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involved in many pathophysiological processes, including regulation of vascular tone, fertility, platelet 
function, tumor biology, and inflammation. Fig. 1 presents a schematic summary of the formation of 
various prostanoids and related lipids. The substrate fatty acids for the action of COX are released from 
membrane phospholipids by phospholipases. COX are bifunctional enzymes that sequentially generate 
PGG2 and PGH2 through a two-step reaction involving the cyclooxygenation and peroxidation of the fatty 
acid substrate, which is mainly arachidonic acid. PGH2 is, in turn, transformed by various synthases into 
the PG and TX. The specific distribution of the various synthases in precise cell types gives PG synthesis 
a cell type–dependent character. Thus, whereas TXA2 is the main product of the COX pathway in 
platelets, PGE2 is synthesized in many different cell types. PGI2, also called prostacyclin, is mainly 
synthesized in endothelial cells and PGD2 is a major COX-pathway product in various types of cells, 
including macrophages, dendritic cells, and activated mast cells[1,2]. Two types of PGD synthase exist, 
known as lipocalin and hematopoietic-PGD synthase, mainly expressed in the central nervous system and 
immune and inflammatory cells, respectively[3]. In addition, it should be taken into account that COX-2 
may act not only on free fatty acids, but also on esters or amides, such as 2-arachidonoylglycerol or 
anandamide. 2-Arachidonoylglycerol is converted into PGH2 glycerol ester, which can be subsequently 
transformed by PG synthases to yield PGE2-, PGF2-, or PGD2-glycerol[4], whereas anandamide is 
transformed into prostanoylethanolamides, such as PGE2 ethanolamide[5]. It is interesting to note that, in 
some cases, products of aspirin-acetylated COX-2, like 15R-HETE, originated in one cell, can be 
metabolized in a different cell, in a process known as transcellular metabolism, giving rise to 15-epi-
lipoxins, which play an important role as proresolution mediators[2,6]. 
 
FIGURE 1. Pathways for the synthesis of prostanoids. COX enzymes acting on polyunsaturated fatty acids generate PG. 
The PG common precursor PGH2 generated from arachidonic acid can subsequently be transformed by synthases into the 
various PG and TXA2. It should be taken into account that nonenzymatic transformation of polyunsaturated fatty acids can 
also give rise to PG through the isoprostane pathway. In addition, nonenzymatic dehydration of some PG leads to the 
formation of reactive cyPG (in yellow ellipses). 
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It is important to note that in addition to enzymatic transformations, PG can be further transformed 
through nonenzymatic reactions, originating a wide variety of structurally and biologically diverse 
prostanoids. For instance, levuglandins, which are highly reactive lipids able to induce protein 
modification and aggregation, can be formed from PGH2 by nonenzymatic rearrangement[7]. 
Nonenzymatic dehydration of PG can also occur, leading to the formation of PG with cyclopentenone 
structure (cyPG), electrophilic lipids with potent anti-inflammatory actions[8,9,10]. Finally, although the 
term prostanoid is used to refer to COX-derived eicosanoids, it should be noted that a substantial amount 
of PGD2 and PGE2 can be formed nonenzymatically by direct oxidation of arachidonic acid through the 
isoprostane pathway[11]. This pathway also gives rise to the isoprostanes, isomers of the PG that may 
display related biological actions[12]. 
Prostanoids play a critical role in inflammation and for many years, COX enzymes and their products 
have been considered mainly proinflammatory agents. Evidence from the use of anti-inflammatory drugs 
and from genetically modified animal models deficient in certain PG synthases or PG receptors have 
evidenced positive roles of prostanoids in the inflammatory response[13]. Thus, PGE2 induces 
hyperalgesia, fever, and pleural exudation; PGD2 facilitates allergic inflammation; and PGI2 plays a key 
role in vasodilatation, inhibits platelet aggregation, and may mediate inflammatory swelling, whereas TX 
is a prothrombotic, platelet-activating prostanoid. Therefore, COX enzymes and PG synthases have been 
key targets for the action of anti-inflammatory compounds and great efforts have been devoted to the 
development of inhibitors. Of the two enzymes of this family, COX-2 is considered the form mainly 
involved in the pathogenesis of inflammation, given the fact that it is not detectable in most tissues, but its 
expression is greatly induced by proinflammatory stimuli (reviewed in Pérez-Sala and Lamas[14]). This 
fact, along with the objective to reduce adverse effects of NSAIDs thought to arise from COX-1 
inhibition, spurred the search for COX-2–specific inhibitors. Several of the new compounds obtained 
through intense research, known generically as the “coxibs”, have produced adverse cardiovascular 
effects, thus revealing more complex roles of COX-2–derived eicosanoids than previously 
contemplated[15,16]. These adverse effects, which include heart failure and myocardial infarction, appear 
to be due to the reduction of vascular synthesis of PGI2, which seems to be largely COX-2 dependent in 
the vascular system, whereas TX synthesis in platelets, dependent on COX-1 activity, is preserved[16]. 
This imbalance would create a vasoconstrictive, prothrombotic state. 
In a work that contributed to changing the view on COX enzymes, Gilroy et al. proposed a role of 
COX-2 in inflammatory resolution[17]. In this work, a late peak of PGD2 production and its dehydration 
product, the cyPG 15-deoxy-12,14-PGJ2 (15d-PGJ2), were observed together with an exacerbating effect 
of NSAIDs at late stages of the inflammatory response. Later, it was reported that mice deficient in 
hematopoietic PGD2 synthase show an exaggerated inflammatory response that fails to resolve 
rapidly[10]. In another study, mice lacking COX-1 or COX-2 showed increased susceptibility to intestinal 
inflammation, more intense in the case of COX-2–deficient animals, thus suggesting a role for COX-2–
derived prostanoids in the defense against inflammation (please see Narumiya[13] for review). These and 
other evidences help to clarify the view that many prostanoids may exert anti-inflammatory actions. The 
nature of the action of prostanoids is highly dependent on the cell type or the target tissue, due in part to 
the type of prostanoid receptors or protein targets present. Thus, the same compound may elicit opposite 
effects in different locations. PGE- and PGD-type PG are clear examples of this and the molecular bases 
for their divergent effects in different biological contexts have been reviewed recently[13,18]. PGE1 was 
early described to ameliorate inflammatory arthritis in animal models[19]. In addition, PGE2 has been 
proposed to regulate the NF-B pathway negatively[20], and both positive and negative effects of this PG 
on inducible nitric oxide synthase (iNOS) induction have been described[14]. The cellular context may 
also influence the nature of the effects encountered. For instance, in some cellular models, PGE2 may 
elicit different effects in the presence and in the absence of cytokine stimulation (see Scher and 
Pillinger[20] for review). Differences in the tissue distribution of PGE2 receptor subtypes underlie many 
of the tissue-specific effects of this PG[1]. PGE2 acting through EP2 and EP4 receptors exerts relaxant 
effects, whereas acting through EP1 elicits contraction of vascular smooth muscle[21]. However, even 
when acting through the same receptor subtype, context is also an important determinant for PG action 
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since, for instance, the same receptor subtype, EP4, has been reported to mediate anti-inflammatory 
actions in intestinal inflammation and proinflammatory effects in arthritis[13].  
PGD2, in turn, has been reported to facilitate allergic reactions. However, PGD2 or its derivatives, in 
particular 15d-PGJ2, have been reported to contribute to the resolution of Th1-driven delayed-type 
hypersensitivity reactions[22]. Two types of PGD2 receptors exist, DP1 and DP2, which signal through 
different mediators and may trigger very different cellular responses. Whereas DP2 is involved in 
leukocyte chemotaxis and allergic inflammation[13], DP1 has been involved both in the development of 
asthmatic responses and in the negative modulation of inflammation[10]. 
Regarding cyPG, recent evidence indicates they may also play opposing roles in different settings. 
Thus, whereas anti-inflammatory effects have been reported in most experimental systems, cyPG may 
elicit proinflammatory effects in precise situations.  
In summary, given their varied effects, a detailed knowledge of the factors that influence PG actions 
is very important in order to predict potential undesirable effects both of PG and of the pharmacological 
inhibition of their synthesis. In this line, the development of novel therapeutics based on the endogenous 
mechanisms of inflammatory resolution and on the identification of novel functions of lipid mediators is a 
thriving field of research. 
ELECTROPHILIC PROSTANOIDS: THE CYCLOPENTENONE PROSTAGLANDINS 
Formation of cyPG 
cyPG are generated by nonenzymatic dehydration of their parent PG. A-series cyPG arise from the 
dehydration of PGE-type PG, whereas cyPG of the J series are generated by dehydration of PGD2 (Fig. 
1). A pathway for the formation of PGA1 in skin has been reported[23]. The pathway for the formation of 
cyPG of the J series has been elucidated in detail. PGJ2 arises from the spontaneous dehydration of PGD2. 
In turn, PGJ2 can be further dehydrated to yield 
12
-PGJ2 in an albumin-dependent manner or 15d-PGJ2 in 
an albumin-independent manner[24]. cyPG were detected in various biological fluids or found to be 
generated in vitro more than 3 decades ago[25,26]. Synthesis of cyPG (reviewed in Noyori and 
Suzuki[27]) allowed the exploration of their biological effects, which unveiled potent antiviral and 
antiproliferative actions[28,29]. Structurally, cyPG are characterized by the presence of an ,-
unsaturated carbonyl group in the cyclopentane ring (cyclopentenone) (Fig. 2). This structure confers a 
strong electrophilicity to the carbon(s) in the -position, which may suffer the nucleophilic attack from 
nucleophiles, mainly the sulfur atom in thiol groups, giving rise to Michael adducts. Thus, conjugates of 
cyPG with glutathione (GSH) or with proteins are generated. From the early studies with cyPG, it was 
realized that the cyclopentenone moiety was a key structure for the activity of these compounds[30]. 
Biological Actions 
As stated above, the effects of cyPG that were pursued earlier were the antiproliferative effects, for 
which they were envisaged as potential anticancer agents. cyPG were found to increase the life span of 
tumor-bearing mice and to inhibit the growth of several transformed cell lines[29,31]. The cellular 
mechanisms involved in the antiproliferative effects of cyPG may be multiple and dependent on the 
biological system under study. cyPG have been shown to induce apoptosis or cell cycle arrest in 
association with modulation of cell cycle regulatory proteins, such as cyclins D1 and B1[32,33], cyclin A– 
and cyclin E–dependent kinases[34], or cyclin-dependent kinase inhibitors[35]. Induction of apoptosis by 
cyPG or cyPG analogs may also result from mitochondria and/or NADPH oxidase–derived oxidative 
stress[36]. CyPG have also been shown to modulate prosurvival and proapoptotic factors. Inhibition of the  
prosurvival factor NF-B has been proposed to play a role in cyPG-induced apoptosis in several settings[37],  
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FIGURE 2. Structures of several cyPG and scheme of the Michael addition. The structure of several 
cyPG of the J or the A series is depicted. Note the variability in the configuration and presence of 
substituents in the lateral chains. Also, the number of electrophilic carbons, marked by asterisks, is 
different. The lower scheme depicts the adduct formed by nucleophilic attack on the carbon in the -
position of the cyPG. 
whereas both positive and negative effects of cyPG on the proapoptotic factor p53 have been 
reported[38,39,40]. In addition, cytoskeletal disruption[41,42,43], inhibition of protein synthesis[44], or 
down-regulation of telomerase reverse transcriptase (hTERT) could play an important role in the 
antiproliferative effects of cyPG[43,45]. Nowadays, the effect of cyPG on cell proliferation has been 
exhaustively studied in a wide variety of experimental models. Although an antiproliferative effect of cyPG 
has been described in most settings, it should be noted that cyPG may also induce cell proliferation and/or 
protection from apoptosis through several mechanisms under various experimental conditions. Protection of 
keratinocytes from apoptosis induced by the carcinogen DMBA has been proposed to be at the basis of an 
increase in cell survival after mutagenic injury and, therefore, of a potentiation of tumor progression[46]. 
Moreover, a protective effect of 15d-PGJ2 on apoptosis induced by H2O2 has been observed in PC12 
cells[47], associated with the induction of the antioxidant response. In hepatic cells, both potentially 
beneficial and adverse effects of cyPG may take place since 15d-PGJ2 has been found to reduce the 
fibrogenic response of human hepatoma cells[48], but enhance the toxicity of allyl alcohol and its active 
metabolite acrolein in isolated hepatocytes[49]. 
Early studies on the biological activity of cyPG also revealed that they are potent antiviral agents. 
This effect was attributed to their ability to inhibit NF-B, which is necessary for the replication of 
several viruses, or to the induction of a heat shock response, which elicits the expression of cytoprotective 
enzymes[50]. More recently it has been shown that certain cyPG may directly target viral proteins 
involved in transcription[51]. Thus, the mechanisms involved in the antiviral effects of cyPG may depend 
on both cellular and viral targets. 
Díez-Dacal and Pérez-Sala: Electrophilic Anti-Inflammatory Prostanoids TheScientificWorldJOURNAL (2010) 10, 655–675 
 
 660 
The studies on the antiviral effects of cyPG, and in particular of PGA1, led to a wealth of knowledge 
on the cellular effects of these compounds. Inhibition of NF-B[52], a transcription factor involved in the 
induction of numerous proinflammatory genes, was noted more than 10 years ago. Since then, the anti-
inflammatory actions of cyPG have been explored in cellular and animal models of inflammation. 15d-
PGJ2 was shown to inhibit the production of monocyte inflammatory cytokines[53], and to reduce the 
expression of iNOS in cerebellar granule cells[54] and in glial cells[55]. 15d-PGJ2 also inhibits COX-2 
and ICAM-1 induction by cytokines[8], as well as the expression and activity of matrix 
metalloproteinases (MMPs)[56]. In addition, potentiation of activated macrophage apoptosis by 15d-PGJ2 
was proposed to contribute to the resolution of inflammation[57], whereas reduction of endothelial cell-
monocyte interaction[58] and decrease in neutrophil migration[59] provided a mechanism for 15d-PGJ2–
mediated inhibition of leukocyte recruitment to the lesion site. In animal models, cyPG have been shown 
to attenuate the development of acute and chronic inflammation[60], to reduce systemic inflammation in 
polymicrobial sepsis[61], and to reduce edema[62]. 15d-PGJ2 may also reduce other inflammatory 
symptoms, such as inflammatory hypernociception[63]. Recently, the use of PGD2 synthase knock-out 
animals indicates that endogenous generation of 15d-PGJ2 plays an important role in limiting the duration 
of the inflammatory process[10]. Inhibition of proinflammatory transcription factors, such as NF-B and 
AP-1, may play a role in the anti-inflammatory actions observed in vitro and in vivo[64]. Similarly, 
activation of the antioxidant response and induction of heme oxygenase-1 (HO-1) has been proposed to 
mediate the anti-inflammatory effects of 15d-PGJ2 in some experimental systems[65]. Indeed, the 
induction of HO-1 itself has anti-inflammatory consequences, in part through the production of CO and of 
bilirubin and biliverdin, which have antioxidant properties. In addition, activation of the transcription 
factor PPAR underlies some of the in vivo reported effects, including attenuation of inflammation in a 
model of experimental stress-induced inflammation[66]. This is due in part to the ability of PPAR to 
interfere with NF-B and AP-1 function. Therefore, although the mechanisms of action involved may be 
multiple and are not completely understood, it is clear that pharmacological doses of cyPG attenuate acute 
and chronic inflammation in several experimental models[60,62,67]. 
Mechanisms of Action 
From the early studies with cyPG, it was recognized that the cyclopentenone structure and the ability of 
these compounds to modify thiol groups covalently was important for their actions. Binding of 
radioactive cyPG to intracellular structures, likely proteins, was evidenced in works by Narumiya and 
Fukushima exploring the subcellular distribution of cyPG[68]. In 1995, the interest in the biological 
effects of cyPG was greatly spurred by the finding that 15d-PGJ2 could act as a ligand for the 
transcription factor PPAR[69], a member of the nuclear receptor family that plays an important role in 
the regulation of lipid metabolism and adipocyte differentiation, and that is also emerging as a key 
regulator of the inflammatory response in some cell types[70]. Although it was not recognized at the 
beginning, it is now clear that 15d-PGJ2 and other endogenous fatty acid derivatives that act as PPAR 
ligands form a covalent adduct with a cysteine residue present in the ligand-binding domain of the factor, 
cysteine 285, and that this interaction is important to elicit the active conformation of the receptor[71,72]. 
Shortly after the connection between cyPG and PPAR activation was proposed, many works 
addressed the potential PPAR-dependent or -independent nature of the effects of 15d-PGJ2. Several 
approaches have been employed, including comparison of the effects of cyPG with those of other PPAR 
agonists, such as rosiglitazone or BRL49653, considered highly selective PPAR agonists, assessment of 
the ability of PPAR antagonists to block cyPG effects, and comparison of cyPG actions with the effects of 
other compounds with different ability to modify proteins covalently. Several works can be cited that 
outline this classical approach[8,73], a schematic view of which is presented in Fig. 3. The involvement 
of PPAR in the effects of cyPG and other agonists has also been studied in cells from conditional  
knock-outs, given the fact that the PPAR knock-out is lethal (see Barak and Kim[74] for review). Recently,  
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FIGURE 3. Contribution of covalent protein modification to the anti-inflammatory effects of cyPG in mesangial cells. A 
summary of the results obtained in rat mesangial cells through the use of various compounds differing in their ability to activate 
PPAR and to modify proteins covalently is shown along with their structure. 15d-PGJ2 efficiently activates PPAR, binds 
covalently to proteins, and elicits anti-inflammatory actions. The analog of 15d-PGJ2, 9,10-dihydro-15d-PGJ2, which lacks the 
endocyclic double bond, but is a potent PPAR agonist, shows greatly reduced ability to inhibit the induction of COX-2 or iNOS 
by cytokines in cellular models. The same applies to rosiglitazone, which is a potent PPAR agonist, but does not bind 
covalently to proteins and does not display anti-inflammatory actions in this system. In contrast, simple cyclic compounds with 
,-unsaturated carbonyls, such as cyclopentenone and cyclohexenone, which are inert as PPAR agonists, display anti-
inflammatory effects. Biotinylated cyPG bind covalently to proteins and mimic many of the effects of their parent PG in spite of 
the presence of the bulky biotin moiety, including disruption of the vimentin cytoskeleton, inhibition of iNOS induction by 
cytokines or induction of permeability transition in mitochondria. Interestingly, biotinylated cyPG appear to be inert as PPAR 
agonists. Taken together, these observations highlight the importance of covalent protein modification over PPAR activation for 
the anti-inflammatory effects of cyPG in mesangial cells. 
depletion of PPAR by RNAi techniques has also been used[75]. In these and other works, it has been 
realized that not only cyPG, but also other PPAR agonists, may display PPAR-independent effects, 
which implies that caution should be exercised when interpreting the results of the pharmacological 
studies in the PPAR field.  
cyPG may also interact with membrane receptors. The DP2 receptor is a chemotactic receptor present 
in various types of leukocytes, which has been involved in allergic inflammation[18]. Several cyPG of the 
J series bind to this receptor with dissociation constants in the nanomolar range[76]. Interaction of cyPG 
with DP2 results in calcium mobilization and chemotaxis of leukocytes. There is no evidence for covalent 
binding of cyPG to DP2. However, cyPG may covalently modify other membrane receptors, such as the 
ion channel TPRA1, resulting in activation[77]. 
As research on cyPG progresses, it becomes clear that these prostanoids may covalently bind to 
multiple cellular targets. Identification of the targets for protein modification by cyPG, some of which 
appear in Fig. 4, has greatly helped the elucidation of their mechanism of action. The potent anti-
inflammatory actions of cyPG rely on the modification of key components of proinflammatory signaling  
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FIGURE 4. Summary of several protein targets for covalent modification by cyPG. Among the protein targets for 
covalent modification by cyPG characterized are transcription factors, receptors, and proteins involved in redox 
control and in protein synthesis and degradation, among others[73,81,141]. 
pathways. The NF-B pathway is activated in response to numerous proinflammatory stimuli and 
mediates the transcriptional induction of genes such as iNOS, COX-2, MMPs, and cytokines. cyPG 
targets along this pathway include IKK, one of the components of the kinase complex that 
phosphorylates the NF-B inhibitory subunit IB, triggering its proteasomal degradation, both the p65 
and p50 subunits of NF-B, and components of the proteasome[78,79,80,81,82]. Thus, cyPG may inhibit 
IB phosphorylation and degradation, which results in a blockade of NF-B nuclear translocation, but 
they may also directly inhibit NF-B DNA binding through addition to cysteines present in the DNA 
binding domain of NF-B subunits (see Stamatakis and Pérez-Sala[41] for review). cyPG interact at 
various levels with the signaling pathways controlling AP-1 activation and, in this case, a direct 
interaction with AP-1 proteins has also been evidenced that results in inhibition of DNA binding[83]. 
Importantly, research in recent years has clearly established the role of cyPG in the stimulation of the 
antioxidant response, through the covalent modification of Keap1 and the subsequent activation of 
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Nrf2[84]. Keap1 is a cysteine-rich protein that serves as a sensor for multiple cysteine-modifying agents, 
redox, and electrophilic stress. Keap1 acts as an adaptor for a ubiquitin ligase and is responsible for the 
proteasomal degradation of Nrf2. Modification of Keap1 impairs Nrf2 degradation by an as-yet-not-
completely-elucidated mechanism, leading to Nrf2 accumulation and nuclear translocation[85]. This 
factor stimulates the transcription of genes that possess an antioxidant-response element (ARE) in their 
promoters, among which are enzymes for GSH synthesis, HO-1, and GST enzymes (reviewed in Nguyen 
et al.[86]). Evidence gathered from many recent works has led to propose a protective role for Nrf2 in 
inflammation[87]. Interestingly, a correlation has been found between the potency of several electrophilic 
compounds of diverse origin as inducers of phase II enzymes and their potency in the suppression of 
inflammation[88]. Moreover, Nrf2 has been proposed to act as a mediator of the anti-inflammatory effects 
of 15d-PGJ2[89]. In summary, Nrf2 and its target genes could play an important role in the resolution of 
inflammation.  
In addition to direct modification by cyPG, redox-sensitive cellular proteins and, in particular, 
transcription factors can be regulated by cyPG through indirect mechanisms. Oxidation-reduction cycles 
are key for the function of several transcription factors, including NF-B, AP-1, p53, and Nrf2. Regarding 
NF-B, for instance, oxidation events in the cytoplasm may contribute to activation, whereas DNA 
binding requires the factor to be in a reduced state. The thioredoxin/thioredoxin reductase (Trx/TR) 
system plays a key role in the reduction of transcription factors. In the case of NF-B, Trx-1 in the 
cytosol can interfere with NF-B activation and nuclear translocation, whereas in the nucleus it enhances 
NF-B activity. The regulation of nuclear redox signaling has been reviewed recently in detail[90]. In the 
nucleus, Trx-1 can reduce transcription factors either directly or indirectly, through the action of a 
multifunctional protein known as APEX or Ref-1. In addition to their ability to induce oxidative stress in 
cells through various mechanisms, cyPG may also directly modify and inhibit both Trx[73] and TR[39], 
thus impairing the capacity of this system to regenerate the reduced forms of transcription factors. It is 
clear then that in inflammation, a situation where both oxidative stress and generation of cyPG occur, the 
possibilities for regulation of transcription factor function are multiple. Understanding these complex 
interactions may open new avenues for therapeutic intervention in the future. 
SELECTIVITY OF PROTEIN MODIFICATION BY cyPG, INTERACTIONS WITH GSH 
AND INDUCTION OF PROTEIN CROSS-LINKING 
cyPG modify multiple cellular proteins. To date, around 100 potential or confirmed targets for cyPG 
modification have been identified in various studies[43,91,92,93,94,95]. Thus, cyPG are emerging as 
pleiotropic mediators with multiple effectors and actions. Analogies can be found between cyPG and 
other mediators able to modify proteins, such as HNE and reactive oxygen or nitrogen species (ROS, 
RNS). In some cases, the cysteine residues targeted by NO or glutathiolation have also been found to be 
modified by certain cyPG. This is the case for C62 in p50, C269 in c-Jun, or C118 in H-Ras[96]. Efforts 
have been devoted to find a consensus sequence for nitrosylation, and recent works outline the importance 
of a neighboring acid-base motif[97]. In the case of cyPG, it has been proposed that cysteine residues 
with a low pKa would be preferentially modified, and that an acidic pH in the vicinity of the adduct 
would contribute to its stability. In addition, steric factors may contribute to defining the binding sites. 
cyPG are structurally very diverse and they differ in the position of the ,-unsaturated carbonyl groups, 
in the structure and orientation of the side chains, and in the presence of one or more electrophilic 
carbons; thus not all cyPG can accommodate in the same protein-binding sites. Therefore, in the complex 
scenario of protein modification by cyPG, there is room for selectivity arising from the structural features 
of both the protein and the cyPG. Indeed, research in recent years has evidenced that protein modification 
by cyPG does not occur randomly. The pattern of cyPG-modified proteins in a given cell type is clearly 
different from the pattern of proteins modified by general cysteine reagents, such as biotinylated 
iodoacetamide, or from that given by total protein staining[8]. Moreover, the proportion in which cellular 
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proteins are modified may be different among cell types. Whereas actin has been shown to be the main 
target for cyPG addition in SH-SY5Y neuroblastoma cells[43], only a minor proportion of total cellular 
actin appears to bind cyPG in NIH-3T3 fibroblasts[94]. The wide structural variety of cyPG provides 
excellent tools to carry out structure-activity studies. In a study with two different biotinylated cyPG, we 
showed by two-dimensional electrophoresis that the subsets of proteins modified by each biotinylated 
analog included common, but also distinct, targets[98]. Moreover, cyPG with different structures may 
target different residues in a given protein. The first examples of this type of selectivity were the H-Ras 
proteins, in which we showed that 15d-PGJ2 binding required the presence of C184, located in the C-
terminal peptide of H-Ras[96], whereas PGA1 bound preferentially to the cysteine located in the GTP-
binding site (C118). The existence of three Ras proteins with highly homologous sequences, but 
diverging at the C-terminal hypervariable domain, allowed us to prove that 15d-PGJ2 bound selectively to 
H-Ras, which is the only Ras protein with a cysteine residue at position 184, whereas PGA1 could bind to 
the three Ras proteins since C118 is present in all of them. Ras protein modification correlated with 
activation of Ras-dependent pathways. Therefore, this study showed that the selectivity of protein 
modification by cyPG can be both inter- and intramolecular, and result in differential biological 
consequences[99]. More recently, it has been shown that 15d-PGJ2 and PGA2 target both common and 
specific cysteine residues of Keap1, although it has been postulated that the common cysteine target 
(C273) is the sensor for these electrophilic compounds leading to the activation of Nrf2[100]. 
One important structural feature of cyPG is the presence of one or more electrophilic carbons, 
resulting from the presence of one or more double bonds conjugated with the carbonyl group (see Fig. 2). 
cyPG with dienone structure may covalently modify two cysteine residues in the same or in different 
proteins, leading to intra- or intermolecular cross-linking. Whereas in the first case important 
conformational changes of the protein can occur, the second possibility may lead to the formation of 
oligomeric species or to protein aggregates. The first protein for which intermolecular cross-linking by 
dienone cyPG was observed was the transcription factor c-Jun[83]. More recently, oligomerization and 
inactivation of citidyltransferase by 15d-PGJ2 has been proposed to result from cysteine cross-
bridging[101]. Taken together, these observations indicate that protein modification by cyPG displays 
structural selectivity, in which both protein and cyPG structural features play an important role. In this 
setting, it would be important to identify factors that may influence the selectivity of protein modification 
by cyPG and, consequently, the biological effects of these lipid mediators. 
In a physiological context, the presence of GSH can be an important factor modulating the selectivity 
of protein modification. GSH is the main, low-molecular-weight antioxidant molecule in cells and it can 
be present at millimolar concentrations. cyPG may form adducts with GSH by enzymatic and 
nonenzymatic mechanisms, and the kinetics and the stability of adduct formation is different depending 
on the structure of the cyPG[102]. This, in turn, affects the availability of cyPG for protein modification. 
This results in protein modification by a single enone such as PGA1 being more dependent on cellular 
GSH levels than modification by a dienone cyPG such as 15d-PGJ2[98]. Moreover, the modulation of the 
binding of cyPG brought about by GSH is not uniform for all polypeptides, thus resulting in different 
patterns of modified proteins. Therefore, GSH levels influence both the extent and the selectivity of 
protein modification by cyPG. 
GST enzymes catalyze the conjugation of GSH with cyPG, the resulting GSH-cyPG conjugates being 
exported from cells by multidrug-resistance transporters[103,104]. GSH concentrations and/or GST 
activity may also influence the subcellular distribution of cyPG[27,80]. Thus, in cells with high cytosolic 
GST activity or GSH content, cyPG has been reported to act preferentially in the nucleus[80]. By using 
biotinylated analogs of cyPG, we have observed that subcellular distribution of cyPG is indeed cell-type 
dependent and it correlates with a compartmentalization of the biological effect. In NIH-3T3 fibroblasts, 
PGA1-B– and 15d-PGJ2-B–modified structures were clearly more abundant in the cytosolic than in the 
nuclear compartment, as assessed both by fluorescence microscopy and subcellular fractionation[94] 
(Gayarre et al., unpublished data). In contrast, mesangial cells[8] and RAW264.7 murine macrophages 
(unpublished observations) showed an even distribution of 15d-PGJ2-B, whereas nuclear accumulation of 
PGA1-B[94] and 15d-PGJ2-B[105] was observed in HeLa cells. These results correlate with the 
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preferential site of action of cyPG with respect to the inhibition of NF-B activation, a paradigmatic 
pathway for cyPG action[64,79,80,81]. As detailed above, cyPG may inhibit NF-B at several levels, 
from the cytosolic signaling steps involving IKK-mediated IB phosphorylation and subsequent 
proteasome degradation to the direct blocking of the binding of NF-B subunits to DNA in the nucleus, 
these events involving the modification of critical cysteine residues in these proteins. Remarkably, in cells 
showing an even cytosolic/nuclear distribution of biotinylated cyPG targets, such as mesangial cells or 
macrophages, both cytosolic and nuclear inhibitory events are inhibited by cyPG[64,80]. In contrast, in 
cells showing preferential nuclear cyPG accumulation, the cytosolic events of NF-B activation, which 
lead to IB degradation and NF-B nuclear translocation, remain unaffected, whereas DNA binding is 
clearly inhibited[81]. A nuclear site for cyPG action has also been reported in the case of microglia[55]. 
Although further work is needed to establish this point unequivocally, these results suggest that 
modulating cytosolic and/or nuclear GSH content or cyPG detoxifying activity may constitute a strategy 
to direct the site of cyPG action.  
EFFECTS OF ENDOGENOUS cyPG AND DUAL ACTIONS 
Unequivocally establishing the role of cyPG as pathophysiological mediators requires assessing the 
effects of the endogenously generated cyPG and solving the discrepancies between the concentrations 
measured in biological systems and those required to elicit biological effects. 
It is worth noting that although 15d-PGJ2 has been the first endogenous compound proposed to act as 
a ligand of PPAR, the dissociation constants measured in most experimental settings are in the 
micromolar range. Since in most works, picomolar or nanomolar concentrations of cyPG have been 
measured, the true pathophysiological role of 15d-PGJ2 as PPAR agonist is under debate. The same 
applies to many of the anti-inflammatory actions, which have been observed only with micromolar 
concentrations of these compounds. Assessing the real concentrations of cyPG in biological systems is 
not an easy task. This is due in part to their high reactivity by which they are rapidly bound to serum or 
intracellular proteins[106]. Thus, the free concentrations of cyPG measured may be an underestimation of 
the real levels. One of the first attempts to determine 15d-PGJ2 levels showed increased generation of this 
cyPG at late stages of the inflammatory process, leading the authors to propose its role in the resolution of 
inflammation[17]. Recently, another work by this group established this point more clearly by showing 
increased 15d-PGJ2 levels in inflammatory exudates of wild-type, but not of PGD2 synthase, knock-out 
animals[10]. Results in this work point to a role of 15d-PGJ2 in modulating the balance of pro- vs. anti-
inflammatory cytokines, and regulating leukocyte influx and monocyte-derived macrophage efflux from 
the inflamed peritoneal cavity to draining lymph nodes leading to resolution. 
Importantly, 15d-PGJ2 has been detected in humans. 15d-PGJ2 was immunodetected in the motor 
neurons of patients with sporadic amyotrophic lateral sclerosis[107]. 15d-PGJ2 has been also detected in 
joint synovial fluid taken from osteoarthritis or rheumatoid arthritis patients[108], and has been shown to 
induce chondrocyte apoptosis in vitro, for which a pathogenic role of 15d-PGJ2 has been suggested. 
Conversely, in a study by Blanco et al., plasma levels of 15d-PGJ2, measured by an enzyme 
immunoassay, were found to be increased in patients with acute stroke with respect to healthy 
controls[109]. However, in this case, levels of 15d-PGJ2 in the group of patients with atherothrombotic 
infarcts were found to be associated with good outcome and smaller infarct volume, thus suggesting a 
neuroprotective effect of 15d-PGJ2 in this condition.  
A summary of the concentrations of cyPG detected in various experimental systems or in 
patients[108,109,110,111,112] is depicted in Fig. 5. 
While the precise assessment of endogenous cyPG levels requires further efforts, it is becoming clear 
that low concentrations of cyPG may also exert important biological effects in experimental settings. 
Repeated addition of nanomolar concentrations of 15d-PGJ2 result in accumulation of cyPG-protein 
adducts over time, leading to biological effects equivalent to those obtained by treating cells with a single  
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FIGURE 5. Concentrations of 15d-PGJ2 measured in different experimental systems and in patients. 
addition of 15d-PGJ2 at micromolar concentrations[106]. Nanomolar concentrations of 15d-PGJ2 have 
been reported to increase proliferation of COX-depleted colorectal cancer cells[113]. Moreover, PPAR 
activation by nanomolar concentrations of 15d-PGJ2 has been reported to inhibit PGE2 production in 
amnion cells[114] and to enhance B-cell proliferation, differentiation, and antibody production[115]. In 
addition, nanomolar concentrations of cyPG acting through the DP2 receptor are able to induce eosinophil 
chemotaxis[116]. 
As outlined above, although antiproliferative and anti-inflammatory activities of cyPG are most 
frequently observed, cyPG may induce the opposite effects in different biological systems. Moreover, in 
several experimental systems, biphasic or dual effects of cyPG have been described that may occur in a 
concentration- or time-dependent manner. A dual effect of cyPG on cell proliferation has been observed 
in several cell types[117]. In endothelial cells, biphasic effects on cell viability occur in association with 
biphasic effects on GSH synthesis[118], with the increase in GSH levels being cytoprotective and GSH 
depletion resulting in cytotoxicity. Interestingly, other inflammatory mediators acting through alteration 
of cellular redox status or modification of protein cysteines have been found to exert biphasic or dual 
effects on various cellular parameters. For instance, NO induces a biphasic regulation of NF-B activity 
that is associated with a dual regulation of iNOS and COX-2 expression in a time-dependent manner in 
mesangial cells[119,120]. Interestingly, we have observed that the cyPG 15d-PGJ2 may elicit a dual 
regulation of iNOS in mesangial cells in a concentration-dependent manner (unpublished observations). 
Similarly, PGA1 may induce a biphasic regulation of COX-2 induction by IL-1 plus TNF- in the same 
system[94]. Thus, hypothetically, cyPG could contribute both to the onset and to the resolution of 
inflammation. 
THERAPEUTIC POTENTIAL AND STRUCTURE-ACTIVITY STUDIES OF cyPG 
An ample number of studies have evaluated the effects of cyPG administration in various in vivo models 
of inflammation or tissue damage, and their potential use as therapeutic agents. The antiproliferative 
potential of cyPG has led to their evaluation as anticancer agents, and some cyPG or cyPG-derived 
compounds have been the subject of extensive preclinical trials. Several formulations containing PGA1 
derivatives have been found to suppress the growth of human ovarian cancer and colon cells inoculated 
into nude mice[121,122]. Moreover, some cyPG derivatives have been found to inhibit proliferation of 
cancer cells resistant to other antitumoral agents[121,123]. For these reasons, efforts are devoted to 
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finding cyPG derivatives with increased stability or potency (Fig. 6)[121,123,124,125,126]. Nevertheless, 
as stated above, assessment of the antitumoral role of cyPG for every particular tumor type is needed 
since potentiation of tumor formation in response to cyPG treatment has been observed in some 
experimental systems in association with increased angiogenesis or protection from apoptosis[46]. 
 
FIGURE 6. Several compounds bearing a PGA1-like reactive moiety that have been studied as potential anti-inflammatory or 
antiproliferative agents. 
Numerous studies have addressed the effects of cyPG on tissue injury, and protective effects of these 
compounds have been evidenced in models of ischemic acute renal failure in rats[127] and 
ischemia/reperfusion injury of the gut[128], among others, which may be due in part to their direct anti-
inflammatory actions or to their ability to activate PPAR. Beneficial effects of cyPG on the 
cardiovascular system have been evidenced in models of restenosis after angioplasty[129] and of 
oxidized, low-density, lipoprotein-induced vascular smooth muscle damage[130]. Moreover, a recent 
formulation based on the structure of PGA2 has shown promising effects on the symptoms of 
atherosclerosis in animal models[131].  
Although beneficial effects have been observed in most cases, some recent studies call attention to 
potential adverse effects of cyPG. In the nervous system, in particular, both neuroprotective and 
neurotoxic actions of cyPG have been reported[132,133]. The identification of cellular targets for cyPG 
may provide valuable information to understand or even predict potential adverse effects of these 
compounds. In addition, given the selectivity of protein modification by cyPG, the wide structural variety 
of cyPG offers the opportunity of performing structure-activity studies and choosing cyPG that modify a 
particular subset of cellular targets. Molecular modeling or crystallographic studies may help in 
understanding the molecular basis for this selectivity, and may serve in the design of compounds targeting 
specific proteins in order to elicit pharmacological or therapeutic actions. 
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Biotinylated analogs of cyPG have been widely used in the identification of cyPG targets. Our recent 
studies have shown that biotinylated cyPG mimic many of the effects of cyPG in cellular models, 
including inhibition of iNOS and COX-2, and induction of HO-1 and Hsp70 expression, but they are 
unable to elicit PPAR activation in vitro or in intact cells[94,134]. Therefore, by adding a bulky moiety to 
the carboxyl group of cyPG, it may be possible to dissociate some biological actions from the PPAR-
agonist activity. This may help to elucidate whether activation of PPAR is an important component of the 
in vivo protective effects of cyPG.  
From a more general perspective, the study of protein modification by electrophilic lipids can be 
important in pharmacology and nutrition. Some active principles present in the diet, such as omega-3 fatty 
acids and phytoprostanes, are taken up by the organism where they are oxidized, giving rise to 
electrophilic species (neuroprostanes) with a reactivity similar to that of cyPG[135,136] and may exert 
anti-inflammatory actions through the covalent modification of proteins involved in proinflammatory 
signaling, such as IKK[137]. Nowadays there is a growing interest in the study of active principles from 
natural products. Among them, we could mention various unsaturated fatty acids, polyphenols, such as 
epillogatecin-galate (present in green tea), curcumin (curry), parthenolide, kamebakaurin, sulforaphane 
(present in broccoli), isoflavones, such as genistein (soy bean), etc. (reviewed in Surh[138]), for many of 
which clinical trials have been conducted (please see http://clinicaltrials.gov/ for detailed information). 
Anti-inflammatory, antioxidant, and antiproliferative or carcinogen-sensitizing effects have been reported 
for these compounds, many of which possess reactivity towards thiol groups and can form adducts with 
cysteines in proteins. For many of these compounds, covalent modification of targets along the NF-B 
pathway has been reported (see Stamatakis and Pérez-Sala[41] for review). The identification of the 
protein targets for these compounds could contribute to the understanding of their mechanism of action. 
From this point of view, the approaches developed in the cyPG field will help in the study of the effects 
of chemoprotective compounds of natural origin acting through electrophilic mechanisms. 
CONCLUDING REMARKS: CROSS-TALK BETWEEN CELLULAR REDOX STATUS, 
PROTEIN MODIFICATION BY cyPG, AND INFLAMMATION 
As it can be inferred from the works reviewed above, cyPG and other electrophilic lipidic mediators are 
contributing to the unveiling of the close interactions that exist between redox and inflammatory 
signaling. Fig. 7 presents a summary of some of these interactions. The modification of cysteine residues 
plays a critical role in this cross-talk and important efforts are being devoted to the characterization of the 
so-called “sulfoproteome”, both regarding the nature of the protein targets and the quantitative aspects of 
cysteine modification. It is clear that cyPG potently alter cellular redox status by multiple mechanisms. 
cyPG may induce potent oxidative stress by acting on mitochondrial proteins and on superoxide-
generating systems[36]. Oxidative stress, in turn, may induce secondary protein modifications, such as 
thiolation[139]. cyPG can also directly modify and impair proteins involved in the regulation of redox 
balance and in the regeneration of redox-sensitive function, such as Trx or TR[39,73], thus affecting other 
redox-responsive proteins indirectly, including transcription factors. Modulation of transcription factors, 
in turn, may widely influence protein expression patterns. For instance, NF-B modulation may affect the 
expression of proteins involved in the generation of RNS, such as iNOS. In addition, cyPG may modulate 
GSH synthesis through activation of Nrf2-dependent transcription that induces the expression of -
glutamyl-cysteine ligase, the rate limiting enzyme in this process[140]. However, the complex actions of 
cyPG on cellular redox status do not constitute a one-way effect. As shown above, the cellular redox 
status and the availability of antioxidant molecules, mainly GSH, clearly influence protein modification 
by cyPG through various mechanisms. It is obvious that irreversible oxidation of cysteine residues under 
conditions of strong oxidative stress would reduce the availability of free thiol groups for potential 
modification by cyPG addition. Moreover, other reactive species may target the same cysteine residues 
than these electrophilic lipids through nitrosylation or thiolation. The pathways for cyPG generation, both  
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FIGURE 7. Reciprocal regulation between cellular redox status and protein modification by cyPG. 
Proteins shown in shaded boxes represent direct targets for cyPG addition. The function of various 
cyPG targets, including redox-sensitive transcription factors, such as NF-B, AP-1, or p53, can be 
regulated by cyPG through multiple mechanisms (see text). 
enzymatic and nonenzymatic, are also subject to regulation depending on the redox status of the cells. 
COX-2 induction, for instance, is highly dependent on the function of redox-sensitive transcription 
factors, such as NF-B or AP-1. GSH content would also influence the cyPG detoxification capacity of 
the cells, since cyPG-GSH adducts can be exported by multidrug transporters[103]. Importantly, GSH 
levels influence the intensity and selectivity of protein modification by cyPG[98]. Finally, as outlined 
above, GSH content may be an important factor in determining the main site of action of cyPG at the 
subcellular level. Therefore, the effects of cyPG on inflammation and, more precisely, on inflammatory 
resolution could be finely tuned by the cross-talk with the redox signaling mechanisms.  
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